Collectively, these findings reveal that PCYT2 inhibited the metastasis of CRC through the PCYT2/PEBP1/YAP1 axis, supporting the significance of metabolic pathways in regulation on cancer metastasis, and they shed light on PCYT2 as a potential therapeutic target for CRC metastasis. Here, PEBP1 is linked to cancer.